Literature DB >> 8649855

Specific binding of MAR/SAR DNA-elements by mutant p53.

B F Müller1, D Paulsen, W Deppert.   

Abstract

Inactivation of the tumor suppressor p53 by single missense point mutations characterizes a large number of human tumors. At least some mutant p53 proteins not only have lost the tumor suppressor function, but at the same time reveal a variety of dominant oncogenic properties. The molecular basis of this 'gain of function' is still unknown. In this report we describe a new biochemical activity of mutant p53, the specific high-affinity interaction with MAR/SAR DNA-elements (nuclear matrix/scaffold attachment regions). This DNA-binding activity can be distinguished from the previously reported DNA-binding activities of p53 by its specificity for mutant p53, the high binding affinity, and the domains of the mutant p53 molecule involved in MAR/SAR DNA-binding. The MAR/SAR-binding region of mutant p53 maps to a bipartite domain consisting of the mutated core region and the C-terminal 60 amino acids, carrying the unspecific DNA-binding domain and the oligomerization motif. MAR/SAR elements are considered as important regulatory elements in a variety of nuclear processes. We propose a model according to which the specific interaction of mutant p53 with MAR/SAR elements might interfere with these processes, thereby exerting pleiotropic oncogenic effects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8649855

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  Clusters of S1 nuclease-hypersensitive sites induced in vivo by DNA damage.

Authors:  J Legault; A Tremblay; D Ramotar; M E Mirault
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  Heritable transgene expression pattern imposed onto maize ubiquitin promoter by maize adh-1 matrix attachment regions: tissue and developmental specificity in maize transgenic plants.

Authors:  François Torney; Anne Partier; Véronique Says-Lesage; Isabelle Nadaud; Pierre Barret; Michel Beckert
Journal:  Plant Cell Rep       Date:  2004-05-04       Impact factor: 4.570

3.  Specific mismatch recognition in heteroduplex intermediates by p53 suggests a role in fidelity control of homologous recombination.

Authors:  C Dudenhöffer; G Rohaly; K Will; W Deppert; L Wiesmüller
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

4.  Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing.

Authors:  K Will; G Warnecke; L Wiesmüller; W Deppert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

5.  Adenovirus type 12-induced fragility of the human RNU2 locus requires p53 function.

Authors:  Z Li; A Yu; A M Weiner
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 6.  Nuclear matrix, dynamic histone acetylation and transcriptionally active chromatin.

Authors:  J R Davie
Journal:  Mol Biol Rep       Date:  1997-08       Impact factor: 2.316

Review 7.  Mutant p53: one name, many proteins.

Authors:  William A Freed-Pastor; Carol Prives
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

8.  Functional analysis of two matrix attachment region (MAR) elements in transgenic maize plants.

Authors:  Lyudmila Sidorenko; Wesley Bruce; Sheila Maddock; Laura Tagliani; Xianggan Li; Michael Daniels; Thomas Peterson
Journal:  Transgenic Res       Date:  2003-04       Impact factor: 2.788

9.  Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: evidence that 15-lipoxygenase is a mutator gene.

Authors:  U P Kelavkar; K F Badr
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

10.  Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.

Authors:  Peixin Dong; Zhujie Xu; Nan Jia; Dajin Li; Youji Feng
Journal:  Mol Cancer       Date:  2009-11-16       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.